glp-1 compounding news Compound versions of drugs for weight loss halted by FDA The risks of using compounding
Description
Tema launched the worlds first GLP-1 Weight Loss ETF in Nov-2023 focused on treating obesity, diabetes and heart disease
But the needs of GLP-1 users could evolve significantly as new drugs come onto the market
At higher doses, absorption consistency becomes critical
Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose insurance refused to cover them
Woodcock and LaVange, 2017)
Approved obesity drugs have improved upon body weight reduction, but, in part, at the expense of lean muscle
